Pricing Log in Create free account
Friday 6 November 2026 Export ARWR’s income statement to Excel — free account

Arrowhead Pharmaceuticals, Inc.

ARWR Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.

Revenue
+171.0%
EPS
−7.94%
Free cash flow
−15.4%
Total debt
+259.5%

Quarter to June 2026, against a year earlier

58.23 0.77 +1.34%
Market cap
$8.1B
P/E
0.0×
Fwd P/E
−16.6×
Dividend yield
—
F-score
5/9
Altman Z
2.98
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Arrowhead Pharmaceuticals, Inc. (ARWR) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Arrowhead Pharmaceuticals, Inc. (ARWR) trades at a P/S ratio of 12.3×. Over the past ten years it has ranged from 2.4× (April 2025) to 2,897× (October 2016); the current reading is higher than 20% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 5.6× (56.43%)
FY2024 12.8× 9.68%
FY2023 11.6× (18.74%)
FY2022 14.3× (69.41%)
FY2021 46.8× (4.98%)
FY2020 49.3× 214.56%
FY2019 15.7× (84.26%)
FY2018 99.5× 850.61%
FY2017 10.5× (99.63%)
FY2016 2,831× 227.42%

Quarterly newest first

Period P/S ratio Change
Jun 2026 17.5× 21.59%
Mar 2026 14.4× 72.15%
Dec 2025 8.3× 49.94%
Sep 2025 5.6× 45.97%
39 more quarters

Against its own ten years

Low 2.4× High 2,897×
Ten-year median 22.2×
Current reading's percentile 22

P/S ratio against peers

Company P/S ratio
CAI Caris Life Sciences,�Inc. compare 7.1×
CORT Corcept Therapeutics Incorporated compare 8.0×
MDGL Madrigal Pharmaceuticals, Inc. compare 8.2×
ARWR Arrowhead Pharmaceuticals, Inc. 12.3×
TWST Twist Bioscience Corporation compare 17.6×
KRYS Krystal Biotech, Inc. compare 18.9×
PTGX Protagonist Therapeutics, Inc. compare 31.7×
CYTK Cytokinetics, Incorporated compare 64.4×
SYRE Spyre Therapeutics, Inc. compare 8,160×
Biotechnology industry median 9.2×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on ARWR